Rongchang Bio received approval from the Hong Kong Stock Exchange to remove the 'B' from its ticker symbol.
On June 7, Rongchang Biological announced that it has received approval from the Hong Kong Stock Exchange and will officially remove the "B" mark from the stock code in the near future.
Rongchang believes that the removal of the "B" mark is seen as an important sign of the development of an 18A biotech company. The "B" means that Rong Chang Biological has reached a higher standard in terms of market value and income, which is another milestone in its history of development.
Rongchang Biological said that in the future, it will make strides toward the goal of becoming a "leading Chinese and world-class" biopharmaceutical company, create more world-class new drugs for patients in China and the world, and create greater value for shareholders and society.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
KLOW80 | GLOW | Peptide | GHK-CU | 99%Purity | Wholesale Custom Peptides
$165-185/UNIT FOB
2026-06-21
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
Zydus Brings the First Keytruda Biosimilar Showdown to North America
-
The FDA Officially Blesses AI for Liver Drug Development
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
Skyrocketing Prices Push Americans to Create Their Own Weight-Loss Drugs
-
Torrent Pharma Nears $2.4 Billion JB Chemicals Buyout Amid Financing Talks
Recommend Reading
-
New Medicines Restore Heart Function in 25 Percent of Heart Failure Patients
-
Indian CRDMOs See Growth as Global Pharma Diversifies Operations
-
US Senator Investigates GSK's Removal of Asthma Inhaler Amid Crisis
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Novo Nordisk Faces $46 Billion Windfall Threatened by Wegovy Missteps and Eli Lilly’s Rise
-
Domo Chemicals’ Triple Collapse: As Chinese Low-Cost Capacity Meets Europe’s Energy Wall, the First Crack Appears in the Continent’s Chemical Empire
-
Post-holiday Increase in Acetone Market Inventory Volume and the Struggle for a Good Start in China
-
Sodium Benzoate (E211): Safety, Benzene Risk, and Preservative Uses
-
The Carbon Tollbooth Is Open: EU’s CBAM Ushers in a New Era of Climate-Linked Trade
-
Pre-holiday Dichloromethane Price Increase Fails to Continue